Safak Mirioglu

👉🏻 Check out this month snapshot summary about CAKUT disease in adult patients doi.org/10.1093/ndt/gf… ✍️Charlotte Hammett is the YNP author Post prepared by @jt_nephrology @NDTsocial @ERAkidney

Great minds, shared ideas, and future collaborations. Sarajevo ERA meeting moments #ERASarajevo2026 #ERAKidney

ERA Education Sarejevo has started! 🔥 @ynptweets has a strong presence within the faculty. 😎

Now open access in @NDTsocial Active lupus nephritis is an orphan disease 🧐Active LN as a rare disease remains overlooked due to limitations in classification, poor disease coding and rigid regulatory thresholds not reflecting clinical reality ▶️academic.oup.com/ndt/article/do…

📢 Join us at the YNP e-seminar jointly organised with YPT (ESOT): *Recurrent IgAN after transplantation* 📅 March 9, 2026 at 5:00 PM (CET) Register now 👉 bit.ly/4kZcC8x

🤩Check out our new Supplement on 'The Treatment Paradigm in IgAN Globally' academic.oup.com/ndt/issue/41/S… 🧐Selected for you: How should we approach the treatment of IgAN in 2025? doi.org/10.1093/ndt/gf… #OpenAccess

23rd International Vasculitis Workshop will be organized in Istanbul, Turkey in 2028. We are excited to host all researchers/clinicians interested in vasculitis in our country..

🪨 Kidney stones: Time to nephrologists to reclaim the field? 👀Check out our latest post with 10 tips on work-up and management of CKD patients with nephrolithiasis. Gerlineke Hawkins-van der Cingel is the YNP author  🧵by @jt_nephrology @CKJsocial @ERAkidney

@SalemAlmaani This was an interesting article on Tupac I read some time ago: jstor.org/stable/25780789

One of the first albums I bought with money I saved. Masterpiece!

What is peptide receptor radionuclide therapy (PRRT) and how is it related to nephrology? 🤔 @NDTsocial @hjanders_hans @ERAkidney 🧵by @smirioglu doi.org/10.1093/ndt/gf…

Excellent, practical recap of the latest lupus nephritis guidelines — definitely worth watching the full webinar if you manage SLE or kidney patients. 🧠🩺

Lupus nephritis: what do new guidelines say? How do the latest international guidelines reshape the diagnosis and management of lupus nephritis (LN)? This e-seminar explores the most recent recommendations from EULAR, KDIGO, and ACR, highlighting key updates, clinical impact, and evidence-based therapeutic strategies to improve patient outcomes. Speaker: Jacob Koopman Speaker: @mxipell Panelist: @smirioglu Moderator/Panelist: Magda Osipyan

Our review on post-transplant thrombotic microangiopathy is online at @CKJsocial! Thanks to all collaborators. @JohannMorelle @OrhanEfe_ @HurdoganOzge @ahmetburakdirim @gizemkumru @KristaLentine @yasar_caliskan doi.org/10.1093/ckj/sf…

🚨 Our newest #InContext on BICARICU-2 trial is online! @CKJsocial @ERAkidney doi.org/10.1093/ckj/sf…

🆕 Review: Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies 📖doi.org/10.1093/ckj/sf…

📢 Join us at new e-seminar series "Podocytopathies in Focus: Challenges and Advances in Management": Management of adult patients with podocytopathies* 📅 January 29, 2026, at 5:00 PM (CET)⁣ The e-seminar is real-time translated into 7 languages: French, German, Italian, Portuguese, Russian, Spanish, and Turkish. Register now 👉 bit.ly/4imVWGO

1/ 🩺 Inflammation and cardiovascular risk in CKD: is IL-8 the missing link? This CKJ study explores the association between IL-8 levels and cardiovascular outcomes in patients with CKD. Maxime Pluquet is the YNP author  🧵 by @jt_nephrology  @ERAkidney @CKJsocial

💥Discover this interesting chapter selected from the ERA Neph-Manual: Systemic diseases and acute glomerulonephritis. This chapter summarises key diseases, the epidemiology, the presentation and the current therapeutic approaches. As the field is evolving, we are moving into an era of targeted and precision medicine in the management of immune-mediated kidney diseases. Don't forget to test your knowledge 👉 bit.ly/48Ta4mU

🚨 Just out from our lab in @CircAHA! 🚨 We know APOL1 risk variants (RVs) cause FSGS. But what about Hypertension-Attributed Kidney Disease (H-CKD)? 🤔 H-CKD is distinct: slowly progressing, low albuminuria, and massive vascular damage. Is it just secondary to kidney injury? Or is it a primary vascular defect? We found the answer.🧵👇ahajournals.org/eprint/TNWJK5I…